Ready to Talk
Colorado?

Contact Our Economic Development and Relocation Experts.

"*" indicates required fields

The information submitted through this form will be used by Colorado BioScience Association (CBSA) and Metro Denver Economic Corporation (MDEDC) for the purpose of evaluating and facilitating economic development opportunities. It will be handled with the utmost confidentiality and will not be disclosed to third parties without explicit consent.

Connector Partner

AGC Biologics

AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,500 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice.

Meet AGC Biologics

Partner News and Insights

AGC Biologics’ Success Highlights Colorado’s Appeal for Life Sciences Companies

AGC Biologics, a global CDMO, operates two major facilities in Colorado. After investing in its Boulder facility in 2020 with support from the state of Colorado and regional economic development groups, the company acquired its Longmont facility in 2021. The recent expansion of AGC Biologics’ Longmont facility enhances the region’s appeal for life sciences companies. Three new Grade B cell therapy suites, featuring cutting-edge modular clean room design and flexible capacity configuration, strengthens the Longmont site’s cell therapy capabilities. This enhancement complements the existing viral vector expansion completed in 2022, which included a range of bioreactor sizes for product development (AMBR, 10L and 50L), and a complete range of commercial manufacturing capacities (50L, 200L, 500L and 2000L), enabling the site to provide support for the entire lifecycle of a product.

The expansion enables AGC Biologics to provide end-to-end cell therapy development and manufacturing services in one location, offering unique benefits to developers seeking comprehensive support for bringing their products to market. With additional space available, AGC Biologics is well-prepared to further expand its cell therapy capabilities to meet the growing market demand. This expansion reinforces Colorado’s position a leading hub for cutting-edge biotech innovation and commercialization.

Click here for the full article.

Let us know!

Ready to Talk
Colorado?

Contact Our Economic Development and Relocation Experts.

The information submitted through this form will be used by Colorado BioScience Association (CBSA) and Metro Denver Economic Corporation (MDEDC) for the purpose of evaluating and facilitating economic development opportunities. It will be handled with the utmost confidentiality and will not be disclosed to third parties without explicit consent.

"*" indicates required fields

Large magenta CO text
Meet Our Partners

Colorado:
Hub for Health Impact

We love to collaborate with new arrivals. Our welcoming life sciences community is right-sized for high-growth companies. There’s more than a million square feet of lab space planned or in development critical infrastructure and state support for startups expansions and relocations. Our supportive partners are ready for every step of the journey.